What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Type 2 Diabetes Clinical Trials 2026: Oral GLP-1s, Retatrutide & Weekly Insulin

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Type 2 diabetes management is being transformed by a wave of new agents in clinical development: oral GLP-1 agonists, multi-receptor agonists, once-weekly basal insulin, and drugs with combined glucose-lowering and organ-protective effects. 2026 is a pivotal year for several Phase 3 readouts that could reshape treatment guidelines.

Oral GLP-1 Agonists: The Most Anticipated Development

Oral administration of GLP-1 agonists has been a pharmaceutical challenge — these peptide drugs are rapidly degraded in the GI tract. Rybelsus (oral semaglutide) was the first approved oral GLP-1, but requires a strict fasting protocol (at least 30 minutes before food) that limits real-world use.

New small-molecule GLP-1 agonists solve this problem. Orforglipron (Eli Lilly) is a non-peptide oral GLP-1 agonist that can be taken at any time regardless of food. Phase 3 ACHIEVE trials showed ~1.3–1.6% HbA1c reduction and ~8–10% body weight loss — comparable to injectable semaglutide. FDA filing is expected in 2026. Danuglipron (Pfizer) is in similar development stages.

Retatrutide: The Triple Agonist

Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. The glucagon component enhances energy expenditure beyond what GLP-1/GIP dual agonists (like tirzepatide) achieve. Phase 2 data showed weight loss of 17–24% over 48 weeks — exceeding any previously approved treatment. Phase 3 trials in type 2 diabetes and obesity are ongoing. Glucose-lowering data from Phase 2 showed superior HbA1c reductions versus comparators.

Once-Weekly Insulin

Daily basal insulin injections are burdensome for patients and associated with adherence challenges. Two once-weekly insulin formulations are in late-stage development:

Insulin icodec (Novo Nordisk): Approved in several countries; Phase 3 ONWARDS trials showed non-inferior HbA1c control with comparable hypoglycemia rates versus daily insulin
Efsitora alpha (Eli Lilly): Phase 3 QWINT trials also demonstrated non-inferiority; FDA submission pending

Organ-Protective Trials

Beyond glucose control, trials are investigating kidney protection (finerenone, sparsentan), cardiovascular risk reduction in high-risk T2D patients, and MASH (metabolic-associated steatohepatitis) — liver disease that disproportionately affects people with diabetes and obesity.

Who Qualifies for Diabetes Trials?

Most T2D drug trials require: established type 2 diabetes diagnosis, HbA1c between 7.0–11.0% (varies by trial), stable background therapy, no severe kidney impairment (eGFR cutoffs vary), and no recent cardiovascular events. Oral GLP-1 trials typically exclude people already on injectable GLP-1 therapy.

Some trials specifically recruit patients not well-controlled on metformin alone, others target insulin-requiring patients. Read eligibility criteria carefully and discuss with your endocrinologist whether a trial might be appropriate for your situation.